Clinical trials: Metastatic Pancreatic Carcinoma
Advanced Cancer, Gastric Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- Minnelide 101 (NCT03129139)
- Testing
- Minnelide™Capsules
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Minneamrita Therapeutics LLC
Gastrinoma, Glucagonoma
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00075439
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
Colorectal Cancer, Locally Advanced
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain.
- Conditions
- Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT00819169
- Testing
- AMG 479, AMG 655
- Volunteers
- 89 people
- Sponsor
- NantCell, Inc.
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
This phase I trial studies the side effects and best dose of CPI-613 when given together with combination chemotherapy in treating patients with metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01835041
- Testing
- 6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Pancreatic Cancer
Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
This is a single arm, open-label Phase II clinical trial to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients with metastatic pancreatic cancer.
- Trial name
- NCT03929094
- Testing
- Paclitaxel for Injection（Albumin Bound）, Gemcitabine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fudan University
Metastatic Pancreatic Cancer
A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)
The aim of this phase 4 study is to evaluate the safety profile of ONIVYDE in China mainland. Primary objective To characterize the safety of ONIVYDE when used under standard clinical practice in China mainland on the following…
- Trial name
- SEOPAC (NCT06688240)
- Volunteers
- 120 people
- Sponsor
- Servier (Tianjin) Pharmaceutical Co. LTD.
Solid Tumors, Colorectal Cancer
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02632448
- Testing
- LY2880070, Gemcitabine
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 229 people
- Sponsor
- Esperas Pharma Inc.
Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
This study will compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX.
- Conditions
- Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation
- Trial name
- PLATINUM-CAN (NCT06783140)
- Testing
- Nab paclitaxel, Gemcitabine, Cisplatin
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Metastatic Pancreas Adenocarcinoma
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic…
- Trial name
- FABLOx (NCT02620800)
- Testing
- 5FU, nab-paclitaxel, bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Celgene
Pancreas Neoplasms
S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
This study will conduct a phase II study of gemcitabine, erlotinib, and S-1 as first-line chemotherapy in patients with advanced pancreatic cancer and evaluate the EGFR expression, KRAS mutation, and BRAF mutation as predictive…
- Trial name
- NCT01693419
- Testing
- GES (Gemcitabine, Erlotinib, S-1)
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Hallym University Medical Center
Metastatic Sarcoma, Esophageal Cancer
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to…
- Conditions
- Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- PHANTOM (NCT06298916)
- Testing
- 64Cu-LNTH-1363S
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Lantheus Medical Imaging
Pancreatic Cancer
Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003591
- Testing
- paclitaxel, radiation therapy
- Where
- 234 sites in United States, Canada
- Volunteers
- 122 people
- Sponsor
- Radiation Therapy Oncology Group
Pancreatic Adenocarcinoma
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with…
- Trial name
- NCT03193190
- Testing
- Nab-Paclitaxel, Gemcitabine, Oxaliplatin
- Where
- 23 sites in United States, Germany and 3 more
- Volunteers
- 341 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.
- Trial name
- ViP (NCT01601808)
- Testing
- Caprelsa (vandetanib)
- Where
- 14 sites in United Kingdom
- Volunteers
- 142 people
- Sponsor
- University of Liverpool
Metastatic Pancreatic Adenocarcinoma
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic).
- Trial name
- NCT06396091
- Testing
- zolbetuximab, mFOLFIRINOX
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pancreatic Adenocarcinoma
A Study of MLN0264 in Patients With Pancreatic Cancer
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with advanced or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the pancreas.
- Trial name
- NCT02202785
- Testing
- MLN0264
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 43 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Adenocarcinoma of the Pancreas, Metastatic Disease
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy
This is a phase II study to see how useful study drug AUY922 is in patients with metastatic pancreatic cancer who have received or are intolerant to first-line chemotherapy.
- Trial name
- NCT01484860
- Testing
- AUY922
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Pancreatic Cancer
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
This is a phase 2 study. All subjects are patients with locally advanced unresectable or metastatic pancreatic cancer harboring KRAS G12D mutation who have received at least one prior line of systemic therapy.
- Trial name
- NCT07784374
- Testing
- GFH375, GFH276, GFS202A
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.